TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35768875

Group type: EXPERIMENTAL
Intervention: Interactive text messaging intervention (iTAB-CV) with daily texts for 2 months, followed by either high or low booster texts for an additional 2 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Self-monitoring of medication taking, mood, and home blood pressure
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Interactive text messaging intervention (iTAB-CV)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Self-monitoring alone
Number of subjects: 200
Study: 33143655

Group type: EXPERIMENTAL
Intervention: Blood group A
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Blood group A (after adjustment)
Number of subjects: 61
Study: 35672892

Group type: EXPERIMENTAL
Intervention: Yinhua Miyanling tablets (YMT) 2 g qid orally
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo (dummy YMT) 2 g qid orally
Number of subjects: 211
Study: 34087717

Group type: EXPERIMENTAL
Intervention: Preoperative combi-elastography (ARIETTA 850, Hitachi Healthcare)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Microvascular invasion (MVI)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: F index
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Prediction model based on laboratory tests, MVI, and F index
Number of subjects: 94
Study: 32993256

Group type: EXPERIMENTAL
Intervention: Butorphanol patient‐controlled intravenous analgesia (0.15 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sufentanil patient‐controlled intravenous analgesia (1.5 μg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Butorphanol patient‐controlled intravenous analgesia
Number of subjects: 100
Study: 36156262

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32614046

Group type: EXPERIMENTAL
Intervention: SocialVille (online social cognition training)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Active control (computer games)
Number of subjects: 108
Study: 32788417

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT) applied in inhibitory mode
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 7
Study: 35466481

Group type: EXPERIMENTAL
Intervention: BB2603-1 (0.01% terbinafine)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Lamisil AT 1% spray
Number of subjects: 46

Group type: COMPARATOR
Intervention: BB2603-1 vehicle control
Number of subjects: 46

Group type: COMPARATOR
Intervention: BB2603-1 vehicle
Number of subjects: 46
Study: 33273276

Group type: EXPERIMENTAL
Intervention: Deep cervical plexus block
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 66
Study: 36686308

Group type: EXPERIMENTAL
Intervention: Fluorescein + methylene blue
Number of subjects: 130

Group type: COMPARATOR
Intervention: Tc‐99 m sulfur colloid + methylene blue
Number of subjects: 130
Study: 33094868

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Systemic family treatment
Number of subjects: 158
Study: 616120200

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2.0mg
Number of subjects: 906

Group type: COMPARATOR
Intervention: Ranibizumab 0.5mg
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 906

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Bimonthly aflibercept
Number of subjects: 906
Study: 34780095

Group type: EXPERIMENTAL
Intervention: NAL‐ER162 (162 mg twice daily)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: NAL‐ER81 (81 mg twice daily)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 33596019

Group type: EXPERIMENTAL
Intervention: Tono-Pen AVIA (TPA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Handheld Goldmann applanation tonometer (GAT)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Comparison of TPA and GAT
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Age increase
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: GAT IOP increase
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CCT increase
Number of subjects: 23
Study: 32933995

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor (PPI) use
Number of subjects: 1360

Group type: COMPARATOR
Intervention: Atezolizumab
Number of subjects: 1360

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 1360
Study: 35412366

Group type: EXPERIMENTAL
Intervention: Major debulking or total/near-total resection
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Leptomeningeal metastatic dissemination before treatment
Number of subjects: 50
Study: 34086752

Group type: EXPERIMENTAL
Intervention: Social support stress management
Number of subjects: 53

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 53
Study: 35709430

Group type: EXPERIMENTAL
Intervention: Food voucher plus pantry
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Home grocery delivery plus pantry
Number of subjects: 117

Group type: COMPARATOR
Intervention: Hospital cancer clinic-based food pantry
Number of subjects: 117
Study: 32891738

Group type: EXPERIMENTAL
Intervention: D-index-guided early antifungal therapy (DET) using micafungin
Number of subjects: 180

Group type: COMPARATOR
Intervention: Empirical antifungal therapy (EAT) using micafungin
Number of subjects: 180
Study: 35857327

Group type: EXPERIMENTAL
Intervention: Text message intervention stating a vaccine had been reserved, with scheduled vaccination date and follow-up reminders.
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group (no text message intervention).
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Text message intervention.
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 2000
Study: 33492269

Group type: EXPERIMENTAL
Intervention: Anisodamine hydrobromide (group A)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (group N)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 107
Study: 32169093

Group type: EXPERIMENTAL
Intervention: Telephone interviews for IADL assessment
Number of subjects: 292

Group type: COMPARATOR
Intervention: Face-to-face interviews for IADL assessment
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Occurrence of falls
Number of subjects: 292
Study: 36047480

Group type: EXPERIMENTAL
Intervention: Educational interventions supported by new technology decision tools for T2DM patients
Number of subjects: 2334

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 2334
Study: 34563211

Group type: EXPERIMENTAL
Intervention: Anakinra (Kineret®), a human recombinant interleukin‐1 receptor antagonist (rhIL1ra)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 20
Study: 34617520

Group type: EXPERIMENTAL
Intervention: Mucoadhesive paste containing PFLC (0.05%) and AFMC (0.01%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mucoadhesive paste containing PFLC and AFMC
Number of subjects: 30
Study: 32917571

Group type: EXPERIMENTAL
Intervention: Autologous fat grafting
Number of subjects: 10
Study: 32178858

Group type: EXPERIMENTAL
Intervention: Remimazolam (HR-7056)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Constant rate infusion of Remimazolam
Number of subjects: 87
Study: 34294072

Group type: EXPERIMENTAL
Intervention: Zinc chloride mouthwash (7.5 ml, rinsed every 8 hours for 2 minutes)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Zinc chloride mouthwash
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 96
Study: 32129114

Group type: EXPERIMENTAL
Intervention: Self‐Harm Antipathy Scale–Swedish Revised (SHAS‐SR)
Number of subjects: 596
Study: 36295581

Group type: EXPERIMENTAL
Intervention: HBOT + OS
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: HBOT
Number of subjects: 171
Study: 32951067

Group type: EXPERIMENTAL
Intervention: 12.5 g Litesse®Ultra (PDX)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 18
Study: 32868594

Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Video instruction
Number of subjects: 31
Study: 36215323

Group type: COMPARATOR
Intervention: Monthly sulfadoxine/pyrimethamine‐amodiaquine (SP‐AQ)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Monthly dihydroartemisinin‐piperaquine (DP)
Number of subjects: 246
Study: 34121333

Group type: EXPERIMENTAL
Intervention: Lower-sodium oxybate (LXB) 4.5 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium oxybate (SXB) 4.5 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower-sodium oxybate (LXB) and sodium oxybate (SXB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower-sodium oxybate (LXB)
Number of subjects: 0
Study: 33577574

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional transarterial chemoembolization (C‐TACE)
Number of subjects: 17
Study: 32058361

Group type: COMPARATOR
Intervention: Load carriage at sea level (SL)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Load carriage at high altitude (HA; 3000 m)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Load carriage at moderate altitude (MA; 2000 m)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Heart rate during TT
Number of subjects: 9
Study: 35550405

Group type: EXPERIMENTAL
Intervention: Avoidance arm (functional lung avoidance based on 3He MRI)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard arm (standard radiation therapy plan without 3He MRI)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 27
Study: 33601689

Group type: EXPERIMENTAL
Intervention: Triple chronotherapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Alternative protocol
Number of subjects: 44
Study: 32212805

Group type: EXPERIMENTAL
Intervention: Gum-chewing group (n=40)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (n=42)
Number of subjects: 82
Study: 34896033

Group type: EXPERIMENTAL
Intervention: 22-gauge needle
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 19-gauge needle
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 22-gauge and 19-gauge needles
Number of subjects: 40
Study: 33241924

Group type: EXPERIMENTAL
Intervention: Home gardening intervention (agricultural training and inputs, nutrition and public health counselling)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Home gardening intervention
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Standard services provided by agriculture and health workers (Control)
Number of subjects: 1006
Study: 35302931

Group type: EXPERIMENTAL
Intervention: Session Model (SM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Daily Model (DM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Weekly Model (WM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All Groups
Number of subjects: 40
Study: 35495896

Group type: EXPERIMENTAL
Intervention: Nursing intervention based on intelligent grip strength system
Number of subjects: 100
Study: 33277303

Group type: EXPERIMENTAL
Intervention: Genetic risk of type 2 diabetes
Number of subjects: 463469
Study: 32398047

Group type: EXPERIMENTAL
Intervention: Canrenone (200 mg intravenously within 2-3 min)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (0.9% saline within the same time)
Number of subjects: 80
Study: 34470583

Group type: EXPERIMENTAL
Intervention: MMPI‐3 over‐reporting scales
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 310
Study: 32446881

Group type: EXPERIMENTAL
Intervention: Edetate disodium
Number of subjects: 633
Study: 33175348

Group type: EXPERIMENTAL
Intervention: Exercise Together (ET)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Exercise Separately (ES)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both groups (ET and ES)
Number of subjects: 9
Study: 34016347

Group type: EXPERIMENTAL
Intervention: VSTAP (3 days of 90 min exercise: 10 min at 30% of PPO + 80 min at 50% of PPO) in heat (35°C-50% RH)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: VSTAP (3 days of 90 min exercise)
Number of subjects: 12
Study: 32978425

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Mean vitamin D level
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Excess weight during the 1st trimester (BMI≥25 kg/m2)
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Arab ethnic group/dark skin colour
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Winter/spring season
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Consumption of milk
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Consumption of yogurt
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Social class
Number of subjects: 793
Study: 35791724

Group type: EXPERIMENTAL
Intervention: Mnemonic Strategy Training (MST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spaced Retrieval Training (SRT)
Number of subjects: 0
Study: 34518248

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 170

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 170
Study: 33971408

Group type: EXPERIMENTAL
Intervention: Freshly formed ferric hydroxide (FFFH) under acidic conditions (pH = 4)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Freshly formed ferric hydroxide (FFFH) under neutral conditions (pH = 7)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Freshly formed ferric hydroxide (FFFH) under alkaline conditions (pH = 10)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: QSAR models established using multiple linear regression (MLR) analysis
Number of subjects: 47
Study: 32595160

Group type: EXPERIMENTAL
Intervention: New warnings on plain packs with innovative texts and pictures based on motivational leverage and harm reduction.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain pack without warning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain pack with conventional warning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Branded pack with conventional warning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monetarily incentivised measures
Number of subjects: 0
Study: 33175237

Group type: EXPERIMENTAL
Intervention: Experimental Group I (EG I) - Theoretically Consistent Approach (TCA), Mindfulness-Based Eating Training (MET), Cash’s Prevention of Body Image Disturbances (CPBID)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Experimental Group II (EG II) - Eclectic Approach (EA), Mindfulness-Based Eating Training (MET), Cash’s Prevention of Body Image Disturbances (CPBID)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Wait List Control Group (CG)
Number of subjects: 129
Study: 33256850

Group type: EXPERIMENTAL
Intervention: Direct admission
Number of subjects: 1696

Group type: COMPARATOR
Intervention: Admission through EDs
Number of subjects: 1696
Study: 35483886

Group type: EXPERIMENTAL
Intervention: FODMAP-lowering diet application
Number of subjects: 459

Group type: COMPARATOR
Intervention: OB (40 mg three times a day)
Number of subjects: 459
Study: 34302924

Group type: EXPERIMENTAL
Intervention: RFM visible during PPV
Number of subjects: 288

Group type: COMPARATOR
Intervention: RFM non-visible during PPV
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: RFM visible
Number of subjects: 288

Group type: COMPARATOR
Intervention: RFM non-visible
Number of subjects: 288
Study: 34973304

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine, 30 mL to 14 mL
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine, 14 mL
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine, 30 mL
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine, 12 mL
Number of subjects: 45
Study: 34684307

Group type: EXPERIMENTAL
Intervention: Healthy Youngsters, Healthy Dads intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 35427803

Group type: EXPERIMENTAL
Intervention: PDS 10 mg/ml
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: PDS 40 mg/ml
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: PDS 100 mg/ml
Number of subjects: 220

Group type: COMPARATOR
Intervention: Monthly ranibizumab 0.5 mg
Number of subjects: 220
Study: 34280067

Group type: EXPERIMENTAL
Intervention: Meloxicam IV 30 mg
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 33176315

Group type: EXPERIMENTAL
Intervention: F + PGA (225 ppm F‐ + 0.1% PGA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: F (225 ppm F‐)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: F + Sn (225 ppm F‐ + SnCl2, 800 ppm Sn2+)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Negative control (distilled water)
Number of subjects: 12
Study: 34337869

Group type: EXPERIMENTAL
Intervention: Telephone intervention based on motivational health coaching
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 106
Study: 35393383

Group type: EXPERIMENTAL
Intervention: Metal plates
Number of subjects: 30

Group type: COMPARATOR
Intervention: Resorbable plates
Number of subjects: 30
Study: 33524326

Group type: EXPERIMENTAL
Intervention: 3-D Plates
Number of subjects: 44

Group type: COMPARATOR
Intervention: Miniplates
Number of subjects: 44
Study: 32275030

Group type: COMPARATOR
Intervention: PECS1 block (Group P)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined PECS1 and TTM blocks (Group PT)
Number of subjects: 30
Study: 35689289

Group type: EXPERIMENTAL
Intervention: Axial ablation (AA) of varicose veins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terminal interruption of the reflux source (TIRS) by peri-ulcer foam sclerotherapy
Number of subjects: 0
Study: 34086740

Group type: EXPERIMENTAL
Intervention: Smartphone application for CTCAE conform symptom reporting and tracking
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard care (no smartphone reporting)
Number of subjects: 66
Study: 36321459

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (97/103 mg twice daily)
Number of subjects: 5661

Group type: COMPARATOR
Intervention: Ramipril (5 mg twice daily)
Number of subjects: 5661
Study: 32049156

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 130

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 130
Study: 34255553

Group type: EXPERIMENTAL
Intervention: Combined hospital-based supervised and home-based unsupervised physical activity sessions (PAS)
Number of subjects: 59
Study: 34053745

Group type: EXPERIMENTAL
Intervention: Combined genetically-influenced lower TG and LDL-C
Number of subjects: 11837

Group type: COMPARATOR
Intervention: Genetically-influenced lower TG only
Number of subjects: 11837

Group type: COMPARATOR
Intervention: Genetically-influenced lower LDL-C only
Number of subjects: 11837

Group type: COMPARATOR
Intervention: Reference group (genetically-influenced high TG and LDL-C)
Number of subjects: 11837
Study: 34184583

Group type: EXPERIMENTAL
Intervention: Syllable Repetition/Prolonged Sounds subtest of the SNAP Test‐R
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Picture‐Cued subtest of the SNAP Test‐R
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paragraph subtest of the SNAP Test‐R
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Syllable Repetition subtest of the SNAP Test‐R
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sound‐Prolonged subtest of the SNAP Test‐R
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal syllables and high vowels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall across all SNAP Test‐R subtests
Number of subjects: 0
Study: 34526064

Group type: EXPERIMENTAL
Intervention: Ketamine infusions (six total)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ketamine infusions (six total) in pain group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ketamine infusions (six total) in non-pain group
Number of subjects: 66
Study: 32503515

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CTRX) plus macrolide
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (ABPC/SBT) plus macrolide
Number of subjects: 263
Study: 32440750

Group type: EXPERIMENTAL
Intervention: 6% HP + TiO2
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 6% HP + TiO2 + chitosan
Number of subjects: 36

Group type: COMPARATOR
Intervention: 35% HP
Number of subjects: 36
Study: 33167920

Group type: EXPERIMENTAL
Intervention: TS-141 30 mg once a day
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: TS-141 60 mg once a day
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: TS-141 120 mg (60 mg twice a day)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 33715574

Group type: EXPERIMENTAL
Intervention: Continuous UST
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pulsed UST
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: UST combined with TENS
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Placebo UST
Number of subjects: 71
Study: 34081779

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Number of subjects: 81

Group type: COMPARATOR
Intervention: Headache education
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction or Headache education
Number of subjects: 81
Study: 32826324

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PLEX)
Number of subjects: 251
Study: 35552788

Group type: EXPERIMENTAL
Intervention: 8-day antibiotic treatment
Number of subjects: 186

Group type: COMPARATOR
Intervention: 15-day antibiotic treatment
Number of subjects: 186
Study: 34270458

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccines (specific vaccines and dosages not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target trial emulation methodology
Number of subjects: 0
Study: 32251012

Group type: EXPERIMENTAL
Intervention: Manualized hearing intervention
Number of subjects: 21